LyncBio Therapeutics raises nearly 100 million RMB in Pre-A funding led by Panlin Capital and Xinge Capital to advance its innovative ADC therapies targeting autoimmune diseases and tumors.

Target Company Overview

LyncBio Therapeutics, founded in September 2023, is an innovative biotechnology firm based in Shanghai that specializes in the research and development of antibody-drug conjugates (ADCs) for treating autoimmune diseases and tumors. The company has developed a proprietary ADC technology platform, focusing on a pipeline aimed at treating intestinal inflammation. Within two years, LyncBio has successfully progressed its ADC development, achieved GMP production, and conducted toxicology studies, currently advancing towards the Investigational New Drug (IND) application stage. This positions LyncBio to potentially fill a significant gap in the global clinical landscape of ADC treatments.

In addition to its core pipeline, LyncBio has multiple other products in early-stage development targeting conditions such as multiple sclerosis, solid tumors across various cancers, and multiple myeloma. This diversified pipeline emphasizes a strategic advantage through the collaborative development of innovative ADC technologies.

Industry Overview in China

China's biopharmaceutical sector has been rapidly evolving, especially in the field of innovative drug development. The increasing prevalence of chronic diseases, particularly autoimmune disorders and various types of cancer, has heightened demand for advanced therapeutic solutions. The gove